


Express Mail Label No.:

Date of Deposit:

Attorney Docket No. 24024-501CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Peled et al.

SERIAL NUMBER: 09/463,320

EXAMINER: Michail A. Belyavskyi, Ph.D.

FILING DATE: January 22, 2000

ART UNIT: 1644

FOR: METHODS OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS

MAIL STOP RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

DECLARATION OF DR. EITAN FIBACH UNDER 37 CFR 1.132

1. I am presently employed as researcher at the Hadassah University Hospital, Department of Hematology, where I am a full professor. I received my Ph. D. degree from the Weizmann Institute of Science in Rehovot, worked as a post-doctoral fellow at the Cancer Research Center, College of Physicians and Surgeons of Columbia University, New York, NY, USA, and was a visiting scientist at the Laboratory of Chemical Biology, NIDDK, National Institutes of Health, Bethesda, MD, USA. My Curriculum Vitae is attached.

2. My research focuses on the development of hematopoietic cells. Since the beginning of my career, I have published more than 150 scientific articles in highly regarded journals and books, and have presented my achievements at many international scientific conferences. I am a member of American Society of Hematology and The International Society of Experimental Hematology. I have served on the editorial board of the journal "Experimental Hematology".

3. I am a co-inventor of the subject matter claimed in the above-referenced U.S. patent application. I have read the Office actions issued with respect to the above-identified application.

4. In the most recent Office action, the Examiner has rejected claims 1-2, 4-13, 15,

37-45 and 47 under 35 U.S.C. § 112, first paragraph as containing subject matter which was not described in the specification in such a way as to enable one of ordinary skill in the art to make and/or use the invention. The Examiner states that while the specification clearly discloses methods of hematopoietic cells transplantation and adoptive immunotherapy by expanding and inhibiting differentiation of CD34+ cells ex vivo, the specification is not enabling for any hematopoietic cells. The Examiner further states that the specification does not teach how to effectively expand and at the same time inhibit differentiation of any hematopoietic cells, and that, the art being unpredictable, given the lack of guidance and working examples, it would take undue trial and error experimentation to practice the claimed invention.

5. I would like to emphasize that while expansion of hematopoietic cells is a well established technique in the art, the present invention is based on a novel method for expanding a population of undifferentiated hematopoietic cells for transplantation and at the same time inhibiting their differentiation, by addition of high affinity copper chelators to the culture medium, in both serum-free and serum-supplemented media, enabling more efficient expansion of stem/progenitor cells as compared with methods previously disclosed in the art.

6. The Examiner has stated that the specification provides enablement only for CD34+ cells that were first isolated (enriched), and then used for ex vivo expansion with the methods of the present invention, using copper chelators and cytokines. I wish to take issue with the Examiner's assertion: in the studies and experiments using the protocols of the present invention and which are described in the specification, we demonstrated, for the first time, that the use of copper chelators is effective in enhancing expansion and inhibiting differentiation in both the CD34+ and murine erythroleukemia undifferentiated cell cultures examined. We demonstrated further that copper chelators have a significant effect on differentiation and growth inhibition of all of the undifferentiated and differentiated cell cultures examined (murine erythroleukemia cells, erythroid precursors from peripheral blood, mononucleocytes, hepatocytes, and embryonal stem cells). Thus, I believe that the specification discloses methods for ex-vivo expansion of and inhibition of differentiation of stem/progenitor cells from a broad range of cells.

7. In another set of experiments described in the specification, I observed that, following our protocols for hematopoietic reconstitution of lethally irradiated mice with bone marrow cells expanded ex vivo with the copper chelator TEPA and cytokines, the mice reconstituted with chelator-expanded bone marrow cells achieved superior WBC recovery and survival as compared to cells expanded with cytokines alone.

8. The Examiner has stated that the instant specification does not teach how to extrapolate data obtained from CD34+ cells ex-vivo assay studies to the development of effective protocols for imposing proliferation and at the same time restricting differentiation of any stem and/or progenitor cells. I would like to present the results of recent experiments using the protocols of the present invention for expansion and inhibition of another undifferentiated cell population, AC 133+ cells.

9. AC 133+ cell lines are important cells in the field of hematopoietic stem cell differentiation. The recent identification and isolation of human hematopoietic cells expressing AC133, has provided a better understanding of the relationships between the cell surface phenotype of the subpopulations comprising the human hematopoietic system and their proliferative and differentiative capacity (see, for example, Bhatia, M., *Leukemia* 2001; 15:1685-88). Studies of cultures of the AC 133+ subpopulation indicate that AC133+ cells have high self-renewal capability, maintain early hematopoietic stem/progenitor cell (HSPC) characteristics, and show superior survival in culture, as compared to CD34+ cells (see Forraz, et al, *Br. J. Haematology*, 2002;119:516-24). Stem cell selection, and many transplantation protocols have now been amended to include identification of candidate cells as AC 133+ as well as CD34+. In a recent series of experiments, we have found that the methods of the present invention for expansion and inhibition of differentiation of cells for transplantation could be easily applied to AC133+.

10. In the experiments described in Appendix I, we compared the results of the application of the methods of the present invention for expanding hematopoietic cells selected according to CD34+, to those selected according to AC 133+. Cord blood derived AC 133+ or CD34+ cells were expanded in culture medium containing MEM α and 10% FCS, thrombopoietin (TPO), interleukin-6 (IL-6), FLT-3 ligand and stem cell factor (SCF),

each at a final concentration of 50 ng/ml, and 5 μ M tetraethylenepentamine (TEPA) (Appendix I, Table 1).

11. As a first step towards large scale experiments and a clinical trial we replaced a research grade **CD34**-based separation device with a clinical grade CliniMACS in combination with the **AC133** CliniMACS reagent. For this purpose, we compared the cell yields and purity following progenitor cell purification utilizing both **CD34** and **AC133** reagents.

12. Cord Blood Units (CBUs) were thawed and the cells were divided into two equal fractions. The enrichment efficacy in terms of cell yield (number of eluted cells) and purity (percent of **CD34**+ or **AC133**+ cells) was comparable following enrichment on CliniMACS utilizing either **CD34** or **AC133** reagents (Appendix I, Fig. 1). Indeed, more than 90% of the **AC133**+ cells were also positive for **CD34**. A representative FACS analysis is shown in Appendix I, Fig 2. CFUc frequency was also comparable in the progenitor cell fraction enriched by the **AC133** reagent to the fraction enriched by the **CD34**+ reagent: 0.2 ± 1.1 and 0.12 ± 0.7 , respectively.

13. We then compared 3 week parameters of cultures (n=4) initiated with a total of 2.5×10^5 **AC133**+ or **CD34**+ cells derived from the same CBU. The yield of TNC was $1065 \times 10^5 \pm 124$ and $760 \times 10^5 \pm 75$, CFUc $81 \times 10^5 \pm 9$ and $83 \times 10^5 \pm 12$, **CD34**+ cells $43 \pm 7 \times 10^5$ and $39 \pm 9 \times 10^5$, **CD34**+**CD38**- cells $12 \pm 3.6 \times 10^5$ and $5.6 \pm 1.3 \times 10^5$, respectively (Appendix I, Fig. 3). In addition, similar proportions of cells expressing myeloid, lymphoid and megakaryocytic phenotype were found in cultures initiated either with **CD34**+ or **AC133**+ cells (Appendix I, Fig 4).

14. Based on these experiments we used the **AC133** CliniMACS reagent in combination with the CliniMACS separation device for the large-scale evaluation of our three weeks expansion procedure.


15. The **AC133** antigen is an important marker for stem/progenitor cells. Numerous phenotypic and functional studies demonstrate that the **AC133**-enriched population could serve as an alternative approach to **CD34**+ cell selection and engraftment purposes.

Furthermore, AC133+ selected cells have been already used in clinical transplantation settings without any safety impairment. Accordingly, our first line of experiments demonstrated similar performance using the CliniMACS instrument and the "MiniMACS CD34 progenitor cell isolation kit" (data not shown).

16. For successful ex vivo expansion, both the number of cells recovered following the enrichment procedure and the purity of the progenitor cell fraction are two crucial parameters. Our results demonstrated similar yield and purity of the fractions recovered following the CliniMACS enrichment procedure utilizing either CD34 or AC133 reagent. Furthermore, following a three week large-scale clinical grade expansion, the yield of CB-derived early progenitor cells in culture initiated with 2.5×10^5 AC133+ cells was statistically similar with that initiated with a same number of CD34+ cells.

17. Thus, not only CD34+, but also AC 133+ cells cultured in the presence of copper chelator, according to the methods of the present invention, exhibit efficient expansion and inhibition of differentiation of hematopoietic stem/progenitor cells. Along with the Examples described in the specification, I believe these results clearly indicate that the methods of the present invention can be successfully extrapolated to populations of undifferentiated cells other than CD34+ cells.

18. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Prof. Eitan Fibach

Signed this day 26 of November, 2003

Enc.:
Curriculum Vitae of Prof. Eitan Fibach
Appendix I

APPENDIX 1

Fig 1:




Fig 2:




Fig. 3a-e: Ex vivo performance of 3 week cultures initiated with either CD34⁺ or AC133⁺ enriched cells n=4




Fig. 3a




Fig. 3b




Fig. 3c




Fig. 3d





Fig. 3e

Fig 4:



Date/ place of birth: June 25th, 1944, Tel-Aviv, Israel.

Ap. B

Nationality: Israeli.

Marital Status: Married plus 2 children.

1962-1965 Military Service.

1965-1970 M.Sc. studies, Department of Microbiology, Tel-Aviv University, Israel.

1968-1969 Consultant in Industrial Microbiology, Decco Food Company, Kibbutz Bror-Hail, Israel.

1969-1970 Research, Central Virology Lab., Ministry of Health, Tel Aviv, Israel.

1970-1975 Ph.D. studies and research with Prof. Leo Sachs, Department of Genetics, Weizman Institute of Science, Rehovot, Israel.
Subject of research: Induction of differentiation in myeloid leukemic cells.

1975-1978 Post-doctorate research with Dr. Paul Marks, Cancer Research Center and Department of Human Genetics and Development, College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Subject: Regulation of differentiation in transformed erythroid cells.

1978- Senior Investigator, Dept. of Hematology, Hadassah University Hospital, Jerusalem, Israel. In charge of the Hemopoiesis and Flow cytometry units.

1982- Department of Biology, The Open University, Tel Aviv, Israel.

1984-1985 Scientific Consultant - Biotechnology General Inc., Rehovot, Israel.

1984-1987 Senior Lecturer, The Hebrew University - Hadassah School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

1987-1996 Associate Professor, The Hebrew University - Hadassah School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

1990-1995 Visiting Scientist, Laboratory of Chemical Biology, NIDDK, National Institutes of Health, Bethesda, MD, USA.

1995-1996 Vice President for research, C. P. Li Biomedical Research Co., Arlington, VA, USA.

1996- Full Professor, The Hebrew University - Hadassah School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Membership in International Societies:

- International Society of Experimental Hematology.
- American Society of Hematology.
- American Society for Photobiology.

Editorial Boards

- Experimental Hematology.
- Cancer Therapy and Control.

September 1999

LIST OF SCIENTIFIC PUBLICATIONS

Eitan Fibach, Ph.D.

1. Fibach, E., Landau, T. & Sachs, L. Normal differentiation of myeloid leukemic cells induced by differentiation inducing protein. *Nature*, 237:276-8, 1972.
2. Fibach, E., Hayashi, M. & Sachs, L. Control of normal differentiation of myeloid leukemic cells to macrophages and granulocytes. *Proc. Nat. Acad. Sci. (USA)*, 70:343-6, 1973.
3. Inbar, M., Ben-Bassat, H., Fibach, E. & Sachs, L. Mobility of carbohydrate containing structures on the surface membrane and the normal differentiation of myeloid leukemic cells to macrophages and granulocytes. *Proc. Nat. Acad. Sci. (USA)*, 70:2577-81, 1973.
4. Fibach, E. & Sachs, L. Control of normal differentiation of myeloid leukemic cells. IV. Induction of differentiation by serum from endotoxin treated mice. *J. Cell. Physiol.*, 83:177-86, 1974.
5. Hayashi, M., Fibach, E. & Sachs, L. Control of normal differentiation of myeloid leukemic cells. V. Normal differentiation in aneuploid leukemic cell and the chromosome banding pattern of D⁺ and D⁻ clones. *Int. J. Cancer*, 14:40-8, 1974.
6. Fibach, E. & Sachs, L. Control of normal differentiation of myeloid leukemic cells. VIII. Induction of differentiation to mature granulocytes in mass culture. *J. Cell. Physiol.*, 86:221-30, 1975.
7. Vlodavsky, I., Fibach, E. & Sachs, L. Control of normal differentiation of myeloid leukemic cells. X. Glucose utilization, cellular ATP and associated membrane changes in D⁺ and D⁻ cells. *J. Cell. Physiol.*, 87:167-78, 1976.
8. Fibach, E., Gerassi, E. & Sachs, L. Colony formation of normal human lymphocytes. *Nature*, 259:127-9, 1976.
9. Fibach, E. & Sachs, L. Control of normal differentiation of myeloid leukemic cells. XI. Induction of specific requirements for viability and growth during the differentiation of myeloid leukemic cells. *J. Cell. Physiol.*, 89:259-66, 1976.
10. Rifkind, R.A., Marks, P.A., Terada, M., Maniatis, G.M., Reuben, R. & Fibach, E. Erythroid differentiation and the cell cycle: Some implications from murine fetal and erythroleukemic cells. *Ann. Immunol. (Inst. Pasteur)* 127c, pp. 887-98, 1976.
11. Rifkind, R.A., Marks, P.A., Bank, A., Singer, D., Terada, M., Maniatis, G.M., Reuben, R. & Fibach, E. Erythroid differentiation studies on the fetal mouse and erythroleukemic cell systems. *Topics in Hematology: Proc. XVI Internat. Cong. of Hematology (Kyoto, Japan, Sept., 1976)*. Seno, S., Takaku, F., Irino, S., eds. Excerpta Medica, Amsterdam-Oxford, 1977, pp. 854-7.
12. Fibach, E., Reuben, R.C., Rifkind, R.A. & Marks, P.A. Effect of hexamethylene bisacetamide on the commitment of differentiation of murine erythroleukemia cells. *Cancer Res.* 37:440-4, 1977.
13. Marks, P.A., Rifkind, R.A., Bank, A., Terada, M., Maniatis, G., Reuben, R. & Fibach, E. Erythroid differentiation and the cell cycle. In: *Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells*. B. Drervinko & R.M. Humphrey, eds. The Williams & Wilkins Pub. Co., Baltimore, 1977, pp. 329-345.

14. Marks, P.A., Rifkind, R.A., Bank, A., Terada, M., Tanaka, M., Ohta, Y., Reuben, R.C. & Fibach, E. Erythroid cell differentiation: Transition of erythroid precursor cells to differentiated cells. Proc. XVI International Cong. of Hematology, Kyoto, Japan, 1976. Seno, S., Takaku, F., Irino, S. eds. Excerpta Medica, Amsterdam-Oxford, 1977, pp. 861-4.
15. Marks, P.A., Rifkind, R.A., Bank, A., Terada, M., Reuben, R., Fibach, E., Nudel, U., Salmon, J. & Gazitt, Y. Induction of differentiation of murine erythroleukemia cells (30th Annual Symposium on Fundamental Cancer Research), 1977.
16. Marks, P.A., Terada, M., Fibach, E., Gazitt, Y., Nudel, U., Reuben, R., Bank, A. & Rifkind, R.A. Induction of murine erythroleukemia cells to differentiate: Cell cycle related events in expression of erythroid differentiation. In: Differentiation of Normal and Neoplastic Hematopoietic Cells. Clarkson, B., Marks, P.A., Till, J., eds. Cold Spring Lab., Cold Spring Harbor, N.Y. 1977.
17. Rifkind, R.A., Fibach, E., Reuben, R.C., Yamasaki, H., Weinstein, I.B., Terada, M., Nudel, U., Gazitt, Y. & Marks, P.A. Erythroleukemia cells commitment to differentiation and the role of the cell surface. In: Differentiation of Normal and Neoplastic Hematopoietic Cells. Clarkson, B., Marks, P.A., Till, J., eds. Cold Spring Laboratory, Cold Spring Harbor, New York, 1977.
18. Yamasaki, H., Fibach, E., Nudel, U., Weinstein, I.B., Rifkind, R.A. & Marks, P.A. Tumor promoters inhibit spontaneous and induced differentiation of murine erythroleukemia cells in culture. Proc. Natl. Acad. Sci. (U.S.A), 74:3451-5, 1977.
19. Nudel, U., Salmon, J., Fibach, E., Terada, M., Rifkind, R.A., Marks, P.A. & Bank, A. Accumulation of alpha and beta globin messengers RNAs in mouse erythroleukemia cells. Cell, 12:463-9, 1977.
20. Ishii, D.N., Fibach, E., Yamasaki, H. & Weinstein, I.B. Tumor promoters inhibit morphological differentiation in cultured mouse neuroblastoma cells. Science, 200:556-9, 1978.
21. Fibach, E., Yamasaki, H., Weinstein, I.B., Rifkind, R.A. & Marks, P.A. Clonal heterogeneity of murine erythroleukemia cells (MELC) to tumor promoter mediated inhibition of cell differentiation. Cancer Res., 38:3685-8, 1978.
22. Rifkind, R.A., Marks, P.A., Bank, A., Terada, M., Reuben, R., Maniatis, G.M., Fibach, E., Nudel, U., Salmon, J. & Gazitt, Y. Regulation of differentiation in normal and transformed erythroid cells. In Vitro, 14:155-61, 1978.
23. Terada, M., Epner, E., Nudel, U., Salmon, J., Fibach, E., Rifkind, R.A. & Marks, P.A. Induction of erythroleukemia differentiation by actinomycin D. Proc. Natl. Acad. Sci. (U.S.A), 75:2795-9, 1978.
24. Terada, M., Nudel, U., Fibach, E., Rifkind, R.A. & Marks, P.A. Changes in DNA associated with induction of erythroid differentiation by dimethylsulfoxide in murine erythroleukemia cells. Cancer Res., 38:835-40, 1978.
25. Marks, P.A., Rifkind, R.A., Terada, M., Reuben, R.C., Gazitt, Y. & Fibach, E. Erythropoiesis - normal erythropoiesis and induced erythroleukemia differentiation. In: Hematopoietic Cell Differentiation. Vol. 10, Golde, D.W., Cline, M.M.J., Metcalf, D. & Fox, C.F. eds. Academic Press, New York, N.Y., 1978.
26. Rifkind, R.A., Fibach, E. & Marks, P.A. Assay for the commitment of murine erythroleukemia cells to differentiate. In: *In vitro* Aspects of Erythropoiesis. Martin J. Murphy, Jr. eds. Springer Verlag, New York-Heidelberg-Berlin, pp. 266-7, 1978.
27. Marks, P.A., Rifkind, R.A., Bank, A., Terada, M., Reuben, R., Fibach, E., Nudel, U., Salmon, J. & Gazitt, Y. Eukaryotic erythroleukemia cells. In: Cell Differentiation and Neoplasia, G.F. Saunders, ed. Raven Press, New York, 1978.

28. Reuben, R.C., Marks, P.A., Rifkind, R.A., Terada, M., Fibach, E., Nudel, U., Gazitt, Y. & Breslow, R. Induction of erythroid differentiation in Friend cells. In: *Oncogenic Viruses and Host Cell Genes*, Ikawa, Y. & Okada, T. eds. Academic Press, New York, 1979.
29. Yamasaki, H., Fibach, E., Weinstein, I.B., Nudel, U., Rifkind, R. & Marks, P.A. Inhibition of Friend leukemia cell differentiation by tumor promoters. In: *Oncogenic Viruses and Host Cell Genes*. Ikawa, Y. & Okada, T. eds. Academic Press, New York, pp. 365-76, 1979.
30. Marks, P.A., Rifkind, R.A., Bank, A., Terada, M., Gambari, R., Fibach, E., Maniatis, G. & Reuben, R. In: *Conference on Cellular and Molecular Regulation of Hemoglobin Switching*, Seattle, WA. Nienhuis, A.W. & Stamatoyannopoulos G. eds. Grune & Stratton, New York, pp. 437-56, 1979.
31. Rifkind, R.A., Fibach, E., Maniatis, G., Gambari, R., Marks, P.A. In: *Conference on Cellular and Molecular Regulation of Hemoglobin Switching*. A.W. Nienhuis & G. Stamatoyannopoulos, eds. Grune & Stratton, New York pp. 421-36, 1979.
32. Fibach, E., Gambari, R., Shaw, P., Reuben, R.C., Sassah, S., Marks, P.A. & Rifkind, R.A. Tumor-promoter-mediated inhibition of cell differentiation: Suppression of the expression of erythroid functions in murine erythroleukemia cells. *Proc. Natl. Acad. Sci. (U.S.A)*, 76:1906-10, 1979.
33. Yamasaki, H., Weinstein, I.B., Fibach, E., Rifkind, R.A. & Marks, P.A. Tumor promoter induced adhesion of murine erythroleukemia cells. *Cancer Res.*, 39:1989-94, 1979.
34. Gambari, R., Fibach, E., Rifkind, R.A. & Marks, P.A. Inhibition of induced murine erythroleukemia cell differentiation by tumor promoters: Relation to the cell cycle. *Biochem. Biophys. Research Comm.*, 94:867-74, 1980.
35. Fibach, E., Marks, P.A. & Rifkind, R.A. Tumor promoters enhance myeloid and erythroid colony formation by mouse hemopoietic cells. *Proc. Natl. Acad. Sci. (U.S.A)*, 77:4152-5, 1980.
36. Fibach, E. & Rachmilewitz, E.A. Tumor promoters induce differentiation in human myeloid cells from patients with acute and chronic myeloid leukemia. *Brit. J. Haemat.*, 47:203-10, 1981.
37. Kornberg, A. & Fibach, E. Thromboplastic activities in leukocytes. *Harefuah*, 101:321-2, 1981.
38. Michaeli, J. & Fibach, E. The clonal origin of the myeloproliferative disorders. *Harefuah*, 101:185-7, 1981.
39. Kidron, M., Fibach, E., Klemes, Y. & Mayer, M. Changes in acid proteolytic activity during differentiation of murine erythroleukemic cells. *Cell Differentiation*, 10:309-15, 1981.
40. Ofer, S., Fibach, E., Kessel, M., Bauminger, E.R., Cohen, S.G., Eikelboom, J. & Rachmilewitz, E.A. Iron incorporation into ferritin and hemoglobin during differentiation of murine erythroleukemia cells. *Blood*, 58:255-62, 1981.
41. Marcus, J.R., Fibach, E. & Aker, M. Circulating myeloid and erythroid progenitor cells in malignant osteopetrosis. *Acta Haematologica*, 67:185-9, 1982.
42. Fibach, E., Treves, A., Peled, T. & Rachmilewitz, E.A. Changes in cell kinetics associated with differentiation of a human promyelocytic cell line (HL-60). *Cell & Tissue Kinetics*, 15:423-9, 1982.
43. Korenberg, A., Treves, A., Rachmilewitz, E.A. & Fibach, E. Generation of procoagulant activity (PCA) by phorbol esters-induced macrophages derived from a leukemic promyelocytic cell line (HL-60). *Blood*, 59:1061-6, 1982.
44. Fibach, E., Peled, T. & Rachmilewitz, E.A. Self-renewal and commitment to differentiation of human leukemic promyelocytic cells (HL-60). *J. Cell Physiol.*, 113:152-8, 1982.

45. Kornberg, A., Fibach, E., Treves, A., Goldfarb, A. & Rachmilewitz, E.A. Circulating erythroid progenitors in patients with "spent" polycythaemia vera and myelofibrosis with myeloid metaplasia. *Brit. J. Haematol.*, 52:573-8, 1982.
46. Morand, O., Fibach, E., Dagan, A. & Gatt, S. Transport of fluorescent derivatives of fatty acids into cultured human leukemic myeloid cells and their subsequent metabolic utilization. *Biochim. Biophys. Acta*, 711:539-50, 1982.
47. Kidron, M., Friedman, D.B., Mayer, M., Klemes, Y. & Fibach, E. Changes in proteolytic activities of human leukemic promyelocytes (HL-60 cells) during maturation. *Hoppe-Seyler's Zeitschrift für Physiologische Chemie*, 363:865-9, 1982.
48. Fibach, E., Peled, T., Treves, A., Kornberg, A. & Rachmilewitz, E.A. Modulation of the maturation of human leukemic promyelocytes (HL-60) to granulocytes and macrophages. *Leukemia Res.*, 6:781-90, 1982.
49. Morand, O., Fibach, E. & Gatt, S. Effect of albumin, low temperature and inhibitors of metabolism on transport of fatty acids into cultured cells. *Biochim. Biophys. Acta*, 613:143-50, 1982.
50. Kornberg, A., Treves, A., Rachmilewitz, E.A. & Fibach, E. Generation of procoagulant activity (PCA) by macrophage-like cells derived from acute and chronic myeloid leukemia patients in response to phorbol esters. *The Scandinavian Journal of Hematology*, 31:102-8, 1983.
51. Fibach, E., Treves, A. & Rachmilewitz, E.A. Spontaneous commitment of murine erythroleukemic cells to terminal differentiation. *Cancer Res.*, 43:4136-41, 1983.
52. Fibach, E., Bauminger, E.R., Konijn, A.M., Ofer, S. & Rachmilewitz, E.A. Iron storage in ferritin following intracellular hemoglobin denaturation in erythroleukemic cells. *Blood*, 62:928-30, 1983.
53. Fibach, E., Kidron, M., Nachshon, I. & Mayer, M. Phorbol ester induced adhesion of murine erythroleukemia cells: possible involvement of cellular proteases. *Carcinogenesis*, 4:1395-9, 1983.
54. Michaeli, J. & Fibach, E. The origin of Reed-Sternberg cells: A solution to the mystery (editorial). *Harefuah*, 105:285-7, 1983. (Hebrew).
55. Fibach, E., Bauminger, E.R., Konijn, A.M., Ofer, S. & Rachmilewitz, E.A. The role of ferritin during hemoglobin synthesis and denaturation in erythroleukemia cells. In: *Structure and Function of Iron Storage and Transport Proteins*, eds. Urushizaki, I., Aisen, P., Listowsky, I. & Drysdale J.W., Elsevier Science Publishers, N.Y. pp 129-132, 1983.
56. Fibach, E., Konijn, A.M. & Rachmilewitz, E.A. Ferritin content during differentiation of human myeloid cell lines. In: *Structure and Function of Iron Storage and Transport Proteins*, eds. Urushizaki, I., Aisen, P., Listowsky, I. & Drysdale J.W., Elsevier Science Publishers, NY. pp 127-8, 1983.
57. Morand, O., Fibach, E., Livni, N. & Gatt, S. Induction of lipid storage in cultured leukemia myeloid cells by pyrene-dodecanoic acid. *Biochim. Biophys. Acta*, 793:95-104, 1984.
58. Klemes, Y., Kidron, M., Mayer, M. & Fibach, E. Inhibition of phorbol ester-induced adhesion of differentiating human myeloid leukemic cells by pentamidine-isethionate. *Differentiation*, 27:141-5, 1984.
59. Fibach, E., Agranat, I. & Rachmilewitz, E.A. Differentiation of human myeloid leukemic cells by phorbol esters: Correlation with tumor promotion. *Int. J. Cancer*, 34:451-7, 1984.

60. Kidron, M., Nachshon, I., Mayer, M. & Fibach, E. Plasminogen activator activity in differentiating leukemia cells. *FEBS Letters*, 177:66-70, 1984.
61. Fibach, E., Konijn, A.M. & Rachmilewitz, E.A. Changes in cellular ferritin content during myeloid differentiation of human leukemic cell lines. *Am. J. Hematol.*, 18:143-51, 1985.
62. Treves, A.J., Fibach, E., Kaizer, N., Weinstein, D., Maoz, H., Halimi, M., Simon, A. & Rachmilewitz, D. Development of macrophage and granulocyte colonies from human peripheral blood. *Int. J. Rad. Oncology Biol. Phys.*, 11:271-5, 1985.
63. Treves, A.J., Fibach, E., Halimi, M., Haimovitz, A. & Fuks, Z. Marker analysis of cloned populations of human monocytes. *Exp. Hematol.*, 13:111-6, 1985.
64. Treves, A.J., Halperin, M., Barak, V., Bar-Tana, R., Halimi, M., Fibach, E., Gamliel, H., Leizerowitz, R. & Polliack, A. A new myelomonocytic cell line (M20): Analysis of properties, differentiation and comparison with other established lines of similar origin. *Exp. Hematol.*, 13:281-8, 1985.
65. Fibach, E., Treves, A., Kidron, M. & Mayer, M. Induction of differentiation in human myeloid leukemic cells by proteolytic enzymes. *J. Cell. Physiol.*, 123:228-34, 1985.
66. Fibach, E., Treves, A., Kornberg, A. & Rachmilewitz, E.A. *In vitro* generation of procoagulant activity by leukemic promyelocytes in response to cytotoxic drugs. *Am. J. Hematol.*, 20:257-66, 1985.
67. Oppenheim, A., Katzir, Y., Fibach, E., Goldfarb, A. & Rachmilewitz, E.A. Hypomethylation of DNA derived from purified human erythroid cell correlates with gene activity of the β -globin cluster. *Blood*, 66:1202-7, 1985.
68. Nahas, N., Fibach, E., Giloh, H. & Gatt, S. Transport of fluorescent fatty acids into cultured cells: analysis by the fluorescence activated cell sorter. In: *Enzymes of Lipid Metabolism-2* (Freysz L, Dreyfuss H, Massarelli R, Gatt S, eds) Plenum Press, New York, 1986, pp 453-8.
69. Manor, D., Fibach, E., Goldfarb, A. & Rachmilewitz, E.A. Erythropoietin activity in the serum of β thalassemia patients. *Scand. J. Haematol.*, 37:221-8, 1986.
70. Michaeli, J., Lerer, I., Rachmilewitz, E.A. & Fibach, E. Stimulation of proliferation of human myeloid leukemia cells in culture: Application for cytogenetic analysis. *Blood*, 68:790-3, 1986.
71. Fibach, E., Nahas, N., Giloh, H. & Gatt, S. Uptake of fluorescent fatty acids by erythroleukemia cells: effect of differentiation. *Exp. Cell Res.*, 66:220-8, 1986.
72. Fibach, E., Morand, E. & Gatt, S. Photosensitization to UV-irradiation and selective killing of cells following uptake of pyrene fatty acid. *J. Cell Science*, 85:149-59, 1986.
73. Oppenheim, A., Peleg, A., Fibach, E. & Rachmilewitz, E.A. Efficient introduction of plasmid DNA into human hemopoietic cells by encapsidation as SV40 pseudovirions. *Proc. Natl. Acad. Sci. (USA)*, 83:6925-9, 1986.
74. Nahas, N., Fibach, E., Giloh, H. & Gatt, S. Use of fluorescence activated cell sorter for studying uptake of fluorescent fatty acids into cultured cell. *Biochem. Biophys. Acta*, 917:86-91, 1987.
75. Oppenheim, A., Karsai, A., Treisman, R., Fibach, E., Treves, A., Goldfarb, A., Maniatis, T., Rachmilewitz, E.A. & Glaser, G. Beta-thalassemia: analysis of mRNA precursors of a mutant human globin gene with defective splicing using peripheral blood nucleated RBC. *Hemoglobin*, 10:573-86, 1987.

76. Fibach, E., Konijn, A.M., Bauminger, R.E., Ofer, S. & Rachmilewitz, E.A. Effect of extracellular hemin on hemoglobin and ferritin content of erythroleukemia cells. *J. Cell. Physiol.*, 130:460-5, 1987.
77. Samara, A., Yagen, B., Agranat, I., Rachmilewitz, E.A. & Fibach, E. Induction of differentiation in human myeloid leukemic cells by T-2 toxin and other trichothecenes. *Toxicology and Applied Pharmacology*, 89:418-28, 1987.
78. Matzner, Y., Gavison, R., Rachmilewitz, E.A. & Fibach, E. Expression of granulocytic functions by leukemic promyelocytic HL-60 cells: differential induction by dimethylsulfoxide and retinoic acid. *Cell Differen.*, 21:261-9, 1987.
79. Fabian, I., Schwartzmayer, S. & Fibach, E. Induction of morphological and functional differentiation of human myeloid leukemia cells (HL-60 and LK) by a benzoic acid derivative of retinoic acid. *Leukemia Research*, 11:863-68, 1987.
80. Fibach, E. & Gatt, S. Clonal analysis of the response of human promyelocytic leukemia (HL-60) cells to photosensitization induced by a pyrene-containing fatty acid. *Leukemia Res.*, 11:1019-26, 1987.
81. Fibach, E. Analysis of the growth kinetics of murine erythroleukemic cells following commitment to terminal differentiation. *Cell and Tissue Kinetics*, 20:617-24, 1987.
82. Gatt, S., Nahas, N. & Fibach, E. Continuous spectrofluorometric measurements of uptake by cultured cells of pyrene dodecanoic acid from its complex with albumin. *Biochem. J.*, 253:377-80, 1988.
83. Gatt, S. & Fibach, E. Spectrofluorometric measurements of the dispersion state of pyrene dodecanoic acid and its uptake by cultured cells and liposomes. *Biochem. Biophys. Acta*, 943:447-53, 1988.
84. Gavison, R., Matzner, Y. & Fibach, E. Differential induction of monocytic functions by dibutyryl cyclic AMP and retinoic acid in a human monoblastic cell line U-937. *Israel J. of Medical Sciences*, 24:697-701, 1988.
85. Fibach, E., Giloh, H., Rachmilewitz, E.A. & Gatt, S. Flow cytofluorometric analysis of the uptake of the fluorescent fatty acid pyrene-dodecanoic acid by human peripheral blood cells. *Cytometry*, 9:525-8, 1988.
86. Yahalom, J., Fibach, E., Bar-Tana, R., Fucks, Z. & Vlodavsky, I. Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix. *Leukemia Res.*, 12:711-7, 1988.
87. Resnick, M., Fibach, E., Lebastard, M., Levy, L. & Bertovier, H. Response of the murine hematopoietic system to chronic infection with mycobacterium lepraemurium. *Infection and Immunity*, 56:3145-51, 1988.
88. Fibach, E., Manor, D., Oppenheim, A. & Rachmilewitz, E.A. Proliferation and maturation of human erythroid progenitors in liquid medium. *Blood*, 73:100-3, 1989.
89. Fibach, E., Rachmilewitz, E.A. & Gatt, S. Analysis of cellular heterogeneity in the response of human leukemic cells to photosensitization induced by pyrene-containing fatty acid. *Leuk. Res.*, 13:1099-1104, 1989.
90. Fibach, E., Gatt, S. & Rachmilewitz, E.A. Selective photosensitization of human leukemic cells by a pyrene-containing fatty acid. *Exper. Hematol.*, 18:89-93, 1990.
91. Fibach, E. & Rachmilewitz, E.A. Proliferation and differentiation of erythroid progenitors in liquid culture: analysis of progenitors derived from patients with polycythemia vera. *Amer. J. Hematol.*, 35:151-6, 1990.

92. Abu-Rabia, S., Fibach, E., Kotler, M. & Gatt, S. Inactivation of vesicular stomatitis virus by photosensitization following incubation with pyrene-containing fatty acid. *FEBS Letts.*, 70:9-10,1990.
93. Kanani, A., Sutherland, D.R., Fibach, E., Matta, K.L., Hindenburg, A., Brockhausen, I., Kuhns, W., Taub, R.N., Van den Eijnden, D.H. & Baker, M.A. Human leukemic myeloblasts and myeloblastoid cells contain the enzyme cytidine 5'-monophosphate-N-acetylneuraminic acid:Galb1-3GalNAc(2-3)-sialyltransferase. *Cancer Res.*, 50:5003-7,1990.
94. Gatt, S., Dinur, T., Abou-Rabia, S., Kotler, M. & Fibach, E. Photosensitization of cultured cells and viruses by pyren-lipids. *Indian Journal of Biochemistry and Biophysics*, 27:359-62, 1990.
95. Fibach, E. & Rachmilewitz, E.A. Erythropoiesis *in vitro*: growth of erythroid progenitors in liquid and semi-solid cultures. *Scritti in onore del Professore Ugo E. Carcassi, Pitsus F. ed.*, Calari, Italy, 1990, pp.171-175.
96. Fibach, E., Manor, D., Treves, A. & Rachmilewitz, E.A. Growth of human normal erythroid progenitors in liquid culture: A comparison with colony growth in semisolid culture. *Inter. J. Cell Cloning*, 9:57-64,1991.
97. Sharon, R. & Fibach, E. Quantitative flow cytometric analysis of ABO red cell antigens. *Cytometry*, 12:545-9,1991.
98. Fibach, E., Peled, T., Fibich, T. & Rachmilewitz, E.A. Isolation and characterization of HL-60 cell variants with different potential for spontaneous differentiation. *Leukemia*, 5:912-6, 1991.
99. Peled, T., Rigel M., Peritt, D., Fibach, E., Treves, A. & Barak, V. The effect of M20 II-1 inhibitor on normal and leukemic human myeloid progenitors. *Blood*, 79:1172-7,1991.
100. Bauminger, ER, Fibach, E., Konijn, AM., Offer, S. & Rachmilewitz, EA. Mossbauer studies of iron uptake, ferritin and hemoglobin synthesis and denaturation in erythroid cell cultures. *Hyperfine Interactions* 66:11-24,1991.
101. Fibach, E. & Rachmilewitz, EA. A two-step liquid culture - a novel culture procedure for studying erythroid cell development. *Hematologia*, 24:211-20,1991.
102. Dalyot, N., Fibach, E., Rachmilewitz, EA. & Oppenheim, A. Adult and neonatal patterns of human globin gene expression are recapitulated in liquid cultures. *Exper. Hematol.*, 20:1141-5, 1992.
103. Fibach, E., Rachmilewitz, EA. & Gatt, S. Photosensitization of human bladder carcinoma cells by pyrene-dodecanoic acid: Quantitative analysis of the cytotoxicity. *Res. Exper. Med.*, 192:185-96,1992.
104. Fibach, E. & Manor, D. Quantitation of serum erythropoietin - what and how to measure ? *Harfua*, 122:655-7,1992. (in Hebrew).
105. Fibach, E., Abu-Rabia, S. & Gatt, S. Pyrene-butanol - an effecient, selective and non-metabolized photosensitizing agent for human myeloid leukemic cells. *Leuk. Res.*, 16:453-62, 1992.
106. Dinur, T., Fibach, E., Suchi, M., Desnick, R.J., Schuchman, E.H. & Gatt, S. Towards gene therapy for Niemann-Pick Disease (NPD): Separation of retroviral corrected and non-corrected NPD fibroblasts using a novel fluorescent sphingomyelin. *Human Gene Therapy*, 3:633-9,1992.
107. Fibach, E. & Rachmilewitz, E.A. Flow cytometric analysis of the ploidy of normoblasts in the peripheral blood of patients with β -thalassemia. *Am. J. Hematol.*, 42:162-5,1993.

108. Fibach, E. & Rachmilewitz, E.A. The two-step liquid culture - novel procedure for studying maturation of human normal and pathologic erythroid precursors. *Stem Cells*, 11(suppl 1):36-41,1993.
109. Fibach, E., Burke, L.P., Schechter A.N., Noguchi, C.T. & Rodgers, G.P. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal and patients with sickle cell anemia or β -thalassemia. *Blood*, 81:1630-5,1993.
110. Fibach, E. Measurement of total and fetal hemoglobin in cultured human erythroid cells by a novel micromethod. *Hemoglobin*, 17:41-53,1993.
111. Epstein, M., Avital, Y., Agmon, V., Dinur, T., Fibach, E., Gatt, S. & Laufer, N. Use of fluorescent lipids for diagnosing a murine embryo model of Gaucher disease. *Human Reproduction*, 8:302-9,1993.
112. Fibach, E. & Rachmilewitz, E.A. Stimulation of erythroid progenitors by high concentrations of erythropoietin results in normoblasts arrested in G2 phase of the cell cycle. *Exp. Hematol.*, 21:184-8,1993.
113. Hanspal, M., Hanspal, J.S. Sahr, K.E. Fibach, E. Nachman, J. & Palek, J. Molecular basis of spectrin deficiency in hereditary pyropoikilocytosis. *Blood* 82:1652-60,1993.
114. Fibach, E., Prasanna, P., Rodgers, G.P. & Samid, D. Enhanced fetal hemoglobin production by phenyl butyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β -thalassemia. *Blood*, 82:2203-2209,1993.
115. Dalyot, N., Fibach, E., Ronchi, A., Rachmilewitz, E.A., Ottolenghi, S. & Oppenheim, A. Erythropoietin triggers a burst of GATA-1 in normal human erythroid cells differentiating in tissue culture. *Nucleic Acid Research*, 21:4031-7,1993.
116. Michaeli, J., Fibach, E. & Rachmilewitz, E.A. Induction of differentiation of myeloid leukemia cells by busulphan: *in vivo* and *in vitro* observations. *Leukemia and Lymphoma*, 11:287-91,1993.
117. Konijn, A.M., Meyron-Holtz, E.G., Fibach, E. & Gelvan, D. A highly regulated pathway for ferritin uptake in human erythroid precursor cells. *Molecular Biology of Hematopoiesis*. Vol. 3, 555-66,1994.
118. Konijn, A.M., Meyron-Holtz, E.G., Fibach, E., Gelvan, D. Cellular ferritin uptake: a highly regulated pathway for iron assimilation in human erythroid precursor cells. *Adv. Exp. Med. Biol.* 356: 189-97,1994.
118. Konijn, A.M., Meyron-Holtz, E.G., Fibach, E. & Gelvan, D. Cellular ferritin uptake - a highly regulated pathway for iron assimilation in human erythroid precursor cells. In: *Progress in Iron Research*. Herskho C, Konijn, A.M. & Eisen P.(eds.), Plenum Press, pp. 189-198, 1994.
119. Myron-Holtz, E.G., Fibach, E., Gelvan, D. & Konijn, A.M. Binding and uptake of exogenous isoferritins by cultured human erythroid precursor cells. *Brit. J. Haematol.*, 86:635-641, 1994.
120. Fibach, E. & Sharon, R. Changes in ABH antigen expression on red blood cells during *in vivo* aging - a flow cytometric analysis. *Transfusion*, 34: 328-332,1994.
121. Finbloom, D.S., Petricoin, E.F., Hackett, R.H. David, M., Feldman, G.M., Igarashi, K., Fibach, E., Weber, M.J., Thorner, M.O., Silva, C.M. & Larner, A.C. Growth hormone and erythropoietin differentially activate the assembly of DNA binding proteins by tyrosine phosphorylation. *Mol. & Cell. Biol.*, 14:2113-8,1994.

122. Fibach, E., Rigel, M., Peled, T., Treves, A.J. & Barak, V. The effect of human myelomonocytic cell line (M20)-derived IL-1 inhibitor on human erythroid cell development. *Leukemia and Lymphoma*, 15:327-332, 1994.
123. Fibach, E., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. Reducing erythropoietin in cultures of human erythroid precursors elevates fetal hemoglobin. *Brit. J. Haematol.*, 88:39-45, 1994.
124. Brodsky, R.A., Hasegawa, A., Fibach, E., Dunbar, C.E., Young, N.S. & Rodgers, G.P. Acquired sideroblastic anaemia following progesterone therapy. *Brit. J. Haematol.*, 87:859-62, 1994.
125. Fibach, E., Hasegawa, S., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. The Two-Phase liquid culture of human erythroid progenitors: Application for studying sickling of erythroblasts from patients with sickle cell anemia (SCA). In "Sickle cell disease and thalassemias: New trends in therapy" Y. Beuzard B. Lubin & J. Rosa, (eds.) Colloque INSERM. V. 234. 1995. John Libbey Eurotext Ltd., Paris. p. 31.
126. Noguchi, C.T., Peters, B. Kolia, P. Fibach, E. & Schechter, A.N. Transcriptional and post-transcriptional modulation of ϵ -globin gene silencing. In "Sickle cell disease and thalassemias: New trends in therapy", Y. Beuzard B. Lubin & J. Rosa, (eds.) Colloque INSERM. V. 234. 1995. John Libbey Eurotext Ltd., Paris. pp. 217-218.
127. Rephaeli, A., Zimra, Y., Nudelman A., Ben-Dror, I., Fibach, E. & Shaklai, M. A novel butyric acid derivative stimulates fetal hemoglobin expression. In "Sickle cell disease and thalassemias: New trends in therapy", Y. Beuzard B. Lubin & J. Rosa, (eds.) Colloque INSERM. V. 234. 1995. John Libbey Eurotext Ltd., Paris. pp. 215-216.
128. Fibach, E., Kolia, P., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. Hemin-Induced acceleration of hemoglobin production in immature cultured erythroid cells: Preferential enhancement of fetal hemoglobin. *Blood*, 85: 2967-74, 1995.
129. Huang, S-Z, Fibach, E., Gu, X-F, Ren, Z-R. & Zeng, Y-T. Normal adult peripheral red cell liquid cultures: Differentiation, maturation and globin gene expression. *Chin J Hematol* 8:403-5, 1995.
130. Noguchi, C.T., Peters, B. Kolia, P. Li, J., Fibach, E. & Schechter, A.N. Transcriptional and post-transcriptional modulation of ϵ -globin gene silencing. In: *Molecular Biology of Hemoglobin Switching*. Stamatoyannopoulos G. ed. Intercept, Andover, U.K. 1995.
131. Epstein, N. Epstein, M. Boulet, A. Fibach, E. & Rodgers, G.P. Antibody based methods for quantitation of hemoglobins: Application to evaluating patients with sickle cell anemia treated with hydroxyurea. *Euro. J. Hematology*, 57:17-24, 1996.
132. Kolia, P., Fibach, E., Najjar, S.M., Noguchi, C.T. & Schechter, A.N. Modifications of RNA processing modulate the expression of hemoglobin genes. *Proc. Nat. Acad. Sci. (USA)*, 93:5693-8, 1996.
133. Hudgins, W.R., Fibach, E., Safaya, S., Rieder, R.F., Miller, A.C. & Samid, D. Transcriptional upregulation of gamma-globin by phenylbutyrate and analogous aromatic fatty acids. *Biochem. Pharmacol.* 52(8):1227-33, 1996.
134. Gelvan, D., Fibach, E., Meyron-Holtz E. G. & Konijn, A.M. Receptor-mediated ferritin uptake by human erythroid precursors is a regulated iron uptake pathway. *Blood*, 88(8):3200-7, 1997.
135. Manor, D., Rachmilewitz, E.A. & Fibach, E. An improved methods for diagnosis of polycythemia vera based on flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture. *Am. J. Hematol.* 54:47-52, 1997.

136. Huang, S-Z, Fibach, E., Gu, X-F, Ren, Z-R, Schechter, A.N, Rodgers, G.P & Zeng, Y-T. The effect of hydroxyurea on the expression of β IVS-II-645 C→T allele. *Chin J Hematol* 17(8):395-8,1996.
137. Kolli, P., Noguchi, C.T., Fibach, E., Loukopoulus, D. & Schechter, A.N. Modification of globin gene expression in cultured erythroid precursors derived from normal individuals: Transcription and post-transcriptional regulation by hemin. *Proc. Assoc. Am. Physicians*, 109(4):1-9,1997.
138. Rund, D., Fibach, E. & Polliack, A. Functional assessment of multidrug resistance gene (MDR1) in hematologic malignancies using rhodamine 123. In "Drug Resistance in Leukemia and Lymphoma II", (R. Pieters, G.J.L. Kaspers and A.J.P. Veerman, eds.) *Advances in Blood Disorders Series* Editor: A. Polliack. 1997, Hardwood Academic Publishers, pp. 275-287.
139. Vaisman, B. Fibach, E. & Konijn, A.M. Utilization of intracellular ferritin iron for hemoglobin synthesis in developing human erythroid precursors. *Blood*, 90:831-838,1997.
140. McCaffrey, P.G., Newsome, D.A., Fibach, E., Yoshida, M. & Su, M.S.-S. Induction of γ -globin by histone deacetylase inhibitors. *Blood*, 90(5):2075-83,1997.
141. Hasegawa, S., Rodgers, G.P., Noguchi, C.T., Blanchette-Mackie, E.J., Usesaka, N., Schechter, A.N. & Fibach, E. Sickling of cultured erythroblasts from patients with sickle cell anemia. *Exper. Hematol.* 26:314-9,1998.
142. Rund, D. Fibach, E. Goldfarb, A. Friedberg, A. & Rachmilewitz, E. Heme arginate therapy for beta thalassemia: *In vitro* versus *in vivo* effects. *Acta Haematol.* 100:82-84, 1998.
143. Fibach, E. The two phase liquid culture procedure for growing human erythroid cells: *In vitro* induction of fetal hemoglobin production. Tutorial workshop on "The Cellular Heterogeneity of Gene Expression and Somatic Variegation". F. Grosveld, D. Higgs, D. Loukopoulos, Y. Beuzard. *European School of Hematology, Fondation Merieux*, 1998.
144. Steiner, H. Polliack, A. Kimchi-Sarfaty, C. Libster, D. Fibach, E. & Rund, D. Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. *Ann. Hematol.* 76: 189-94,1998.
145. Fibach, E. Techniques for studying stimulation of fetal hemoglobin production in human erythroid cultures. *Hemoglobin*, 22 (5-6):445-453, 1998.
146. Paterakis, G.S., Thein, S.L., Fibach, E. & Capellini, M.D. Cross evaluation of three flow cytometric F-cell counting methods performed by different laboratories. *Hemoglobin*, 22 (5-6):427-444, 1998.
147. Fibach, E. Stimulation of fetal hemoglobin production - a novel therapeutic approach for β -hemoglobinopathies (Review) *Tazpit*, 2:14-17,1998 (Hebrew).
148. Vaisman, B., Santambrogio, P., Arosio, P., Fibach, E. & Konijn, A.M. An ELISA for the H-subunit of human ferritin employing a combination of rabbit poly- and mice monoclonal antibodies and an enzyme labeled anti-mouse-IgG. *Clin chem Lab Med* 37(2):121-125,1999.
149. Vaisman, B., Konijn, A.M. & Fibach, E. Purification of developing human erythroid precursors by immunomagnetic separation. *Acta Haematol.* 101:135-139,1999.
150. Asimakopoulos, A.F., Shteper, P.J., Krichevsky, S., Fibach, E. Polliack, A., Rachmilewitz, E., Ben-Neriah, Y. & Ben-Yehuda, D. c-ABL methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. *Blood*, in Press.
151. Meyron-Holz, E.G., Vaisman, B., Cabantchik, Z.I., Slotki, I.N., Fibach, E., Rouault, T.A., Konijn, A.M. Regulation of intracellular iron metabolism in human erythroid precursors by internalized extracellular ferritin. *Blood*. in press.

152. Asimakopoulos, A.F., Shteper, P.J., Fibach, E. Polliack, A., Rachmilewitz, E., Ben-Neriah, Y. & Ben-Yehuda, D. Prognostic significance of c-ABL methylation in chronic myeloid leukemia: Still an open question. *Blood*, letter, 94(3):1141,1999.

153. Hirshberg, B., Shouval, D. Fibach, E. Friedman, G. and Ben-Yehuda, D. The role of flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture in the detection of occult polycythemia vera in the Budd-Chiari syndrome. *J. Hepatol.* in press